- CSPC Pharma’s fiscal year revenue was 29.01 billion yuan, falling short of the estimated 29.56 billion yuan.
- The company reported external sales of finished drugs at 23.72 billion yuan, below the forecasted 24.28 billion yuan.
- Net income for CSPC Pharma was 4.33 billion yuan, missing the expected 4.77 billion yuan.
- The final dividend announced was 10 Hong Kong cents per share.
- Underlying profit was reported at 4.68 billion yuan.
- Market analyst recommendations include 22 buys, 12 holds, and 1 sell for CSPC Pharma.
A look at CSPC Pharmaceutical Group Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 5 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, CSPC Pharmaceutical Group shows strong potential for long-term growth and stability. With high scores in Value, Dividend, Growth, Resilience, and slightly lower in Momentum, the company is well-positioned in key areas. The company’s focus on manufacturing and selling pharmaceutical products, including widely-used medications like vitamin C and antibiotics, coupled with its efforts in developing innovative drugs, bodes well for its future prospects.
Investors looking for a company with solid fundamentals and a commitment to dividends may find CSPC Pharmaceutical Group appealing. Its high scores in Value, Dividend, Growth, and Resilience indicate a balanced performance across key factors. Despite a slightly lower score in Momentum, the company’s diversified product portfolio and focus on innovation in the pharmaceutical industry offer a promising outlook for long-term investment.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
